MONTREAL, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Healthtech company, announces the appointment of Guy Daoust as the Corporation’s new Chief Financial Officer, effective immediately.
“It is with great pleasure that we welcome Guy to our team. He will make a great addition to the senior leadership team as we continue executing on our growth strategy,” said Martin Legault, Chief Executive Officer. “Guy’s wide experience will benefit Premier Health and its shareholders at many levels.” he added.
Guy Daoust has been part of the management team of a publicly traded Canadian company for more than 15 years. Over that period, he held leadership positions in financing, investments, treasury, accounting, and risk management. He led debt and equity issuances totaling nearly $7 billion and played key roles in supporting that company’s sustained growth in Canada and abroad. Guy is a member of the Ordre des comptables professionnels agrées du Québec (CPA).
Interim Chief Financial Officer Simon Belval who joined Premier Health in September 2022 will continue with the Corporation for a transition period.
“Simon made a significant contribution to our organisation. Thanks to his strong capacity to adapt and problem-solving skills, he performed a smooth and efficient transition, including the roll-out of our ERP system.” said Martin Legault.
About Premier Health
Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary PSweb platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper, and more accessible care services.
For Further Information Please Contact:
Mr. Jean-Robert Pronovost
Vice-President, Corporate Development
Premier Health of America Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it. / 1 800 231 9916
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedar.com.
Last Trade: | C$0.14 |
Daily Volume: | 11,500 |
Market Cap: | C$7.770M |
November 14, 2024 August 21, 2024 May 23, 2024 February 26, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB